2022 - Research.com Best Scientist Award
2020 - Member of the National Academy of Medicine (NAM)
2013 - Distinguished Scientist Award, American Heart Association
Member of the Association of American Physicians
Paul M. Ridker mostly deals with Internal medicine, Endocrinology, Myocardial infarction, C-reactive protein and Risk factor. He combines subjects such as Surgery and Cardiology with his study of Internal medicine. He has researched Endocrinology in several fields, including Odds ratio and Genome-wide association study.
His Myocardial infarction research focuses on subjects like Disease, which are linked to Intensive care medicine and Bioinformatics. His C-reactive protein research incorporates elements of Gastroenterology, Framingham Risk Score and Metabolic syndrome. His research integrates issues of Clinical trial, Epidemiology, Relative risk, Blood pressure and Vascular disease in his study of Risk factor.
His scientific interests lie mostly in Internal medicine, Endocrinology, C-reactive protein, Myocardial infarction and Cardiology. The concepts of his Internal medicine study are interwoven with issues in Diabetes mellitus and Surgery. His Endocrinology research is multidisciplinary, relying on both Gastroenterology, Rosuvastatin and Odds ratio.
Paul M. Ridker regularly ties together related areas like Vascular disease in his C-reactive protein studies. His Myocardial infarction study combines topics in areas such as Stroke, Aspirin, Epidemiology and Cohort. Paul M. Ridker has included themes like Framingham Risk Score and Blood pressure in his Cardiology study.
His primary scientific interests are in Internal medicine, Genome-wide association study, Genetics, Disease and Hazard ratio. His Internal medicine research is multidisciplinary, incorporating elements of Placebo and Oncology. As part of the same scientific family, Paul M. Ridker usually focuses on Genetics, concentrating on Meta-analysis and intersecting with Risk factor.
His study in Disease is interdisciplinary in nature, drawing from both Inflammation, Epidemiology and Cohort. His Hazard ratio study combines topics from a wide range of disciplines, such as Gastroenterology, Cancer, Prospective cohort study and Odds ratio. His studies in Myocardial infarction integrate themes in fields like Stroke, Diabetes mellitus and Coronary artery disease.
His primary areas of study are Internal medicine, Genome-wide association study, Genetics, Hazard ratio and Genetic association. His Internal medicine study combines topics from a wide range of disciplines, such as Placebo and Oncology. Paul M. Ridker combines subjects such as Genetic architecture, Mendelian Randomization Analysis, Polymorphism and Medical genetics with his study of Genome-wide association study.
Paul M. Ridker has researched Genetics in several fields, including Blood lipids, Cholesterol and Lipid metabolism. His Genetic association study combines topics in areas such as Pulse pressure, Blood pressure, Bioinformatics, Case-control study and Expression quantitative trait loci. The concepts of his Myocardial infarction study are interwoven with issues in Stroke, Diabetes mellitus and C-reactive protein.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Inflammation and Atherosclerosis
Peter Libby;Paul M. Ridker;Attilio Maseri.
C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
Paul M Ridker;Charles H Hennekens;Julie E Buring;Nader Rifai.
The New England Journal of Medicine (2000)
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M Ridker;Eleanor Danielson;Jacques Genest;Antonio M. Gotto.
The New England Journal of Medicine (2008)
Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
Paul M. Ridker;Mary Cushman;Meir J. Stampfer;Russell P. Tracy.
The New England Journal of Medicine (1997)
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Paul M. Ridker;Eleanor Danielson;Francisco A. H. Fonseca;Jacques Genest.
Obstetrical & Gynecological Survey (2009)
COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
R Altman;L Carreras;R Diaz;E Figueroa.
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Aruna D. Pradhan;JoAnn E. Manson;Nader Rifai;Julie E. Buring.
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
Paul M. Ridker;Nader Rifai;Lynda Rose;Julie E. Buring.
The New England Journal of Medicine (2002)
From Vulnerable Plaque to Vulnerable Patient A Call for New Definitions and Risk Assessment Strategies: Part I
Morteza Naghavi;Peter Libby;Erling Falk;S. Ward Casscells;S. Ward Casscells.
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M Ridker;Brendan M. Everett;Tom Thuren;Jean G. MacFadyen.
The New England Journal of Medicine (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: